The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Publications hub
Find our publications, laboratory reports, meeting minutes and statements, and scheduling decisions.
We’re still confirming the best location for some of our content. Can't find what you’re looking for? You can also:
-
search our Resources
-
use the site search bar in the top right of this screen for more results.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- Advisory bodies and committees (357)
- Scheduling (national classification system) (155)
- Prescription medicines (34)
- Advertising (24)
- In Vitro Diagnostic medical devices (IVDs) (24)
- Medicine safety (22)
- Therapeutic goods regulation (19)
- Medical devices safety (13)
- Manufacturing (11)
- Safety (10)
- Complementary medicines (9)
- Non-prescription medicines (9)
- Over the counter (OTC) medicines (8)
- COVID-19 vaccines (7)
- Listed medicines (7)
- Regulatory compliance (7)
- COVID-19 (6)
- Registered complementary medicines (6)
- Assessed listed medicines (5)
- Medicinal cannabis hub (5)
- Shortages (4)
- Fees and payments (3)
- Legislation (3)
- Alert/Advisory (2)
- Clinical trials (2)
- Compliance and enforcement hub (2)
- Import and export (2)
- Sunscreens (2)
- Artificial Intelligence (AI) (1)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Biological medicines (1)
- Breast implant hub (1)
- Cosmetics (1)
- Disinfectants/Sterilants (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Pharmacovigilance (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
705 result(s) found, displaying 1 to 25
-
PublicationsDetailed statistical information on Therapeutic Goods Administration performance in pre- and post-market activities.
-
PublicationsThis report provides information about our regulatory performance for the 2023-24 financial year.
-
Scheduling decisions (interim)Interim decisions on proposed amendments to the Poisons Standard closing 4 April 2025
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 50 held 4 December 2024
-
Meeting statementsAdvisory Committee on Vaccines Statement 51 for meeting held 5 February 2025
-
Meeting statementsAdvisory Committee on Vaccines meeting Statement 49 for meeting held 2 October 2024
-
Meeting statementsMeeting statement from the 15th Consumer Working Group meeting that took place on 8 November 2024.
-
Scheduling decisions (interim)We have reopened the consultation on the interim decision regarding IV potassium in recognition of the broad impact of the proposed changes
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations).
-
PublicationsThis report provides an overview of pharmacovigilance inspection deficiencies in 2022, including a comparison to results from previous reporting periods.
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
PublicationsThe findings will inform the need for any risk management actions to ensure public safety.
-
Scheduling decisions (final)Publication of the decisions made by a delegate of the Secretary in relation to to nicotinic acid.
-
PublicationsThis plan outlines our compliance and education priorities for 2024-2025.
-
Meeting statementsRead the meeting statement from 12 December 2024 meeting of the Advisory Committee on Medical Devices.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsCommunique from the 1st meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 27 November 2024
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 March 2024
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Scheduling decisions (interim)We are seeking submissions for a consultation on the interim decisions for IV potassium salts and nicotinic acid.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
PublicationsRead our 2024 stakeholder survey report, which aims to improve the way we work with our stakeholders.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Summary report of residual DNA and endotoxin on COVID-19 mRNA vaccines conducted by TGA Laboratories
TGA laboratory testing reportsThe TGA has conducted a comprehensive evaluation of the residual DNA and endotoxin levels in the two mRNA vaccines supplied in Australia - Comirnaty (Pfizer) and Spikevax (Moderna).